GlucoTrack ( (GCTK) ) has issued an announcement.
On March 19, 2025, Glucotrack announced that it will present safety and performance data from its first-in-human trial of its continuous blood glucose monitoring (CBGM) system at the 2025 International Conference on Advanced Technologies & Treatment for Diabetes in Amsterdam. The CBGM system, which measures glucose directly from the blood without on-body wearables, is designed for long-term use and aims to offer more accurate and less intrusive glucose monitoring. This presentation marks a significant step in advancing Glucotrack’s clinical program and could potentially transform diabetes management.
More about GlucoTrack
Glucotrack, Inc. (NASDAQ: GCTK) is a medical device company focused on designing, developing, and commercializing novel technologies for people with diabetes. The company is currently developing a long-term implantable continuous blood glucose monitoring system.
YTD Price Performance: -95.21%
Average Trading Volume: 3,934,017
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $3.72M
For a thorough assessment of GCTK stock, go to TipRanks’ Stock Analysis page.